Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 15INDUSTRY 11NIH 7UNKNOWN 1OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1

Interventions

Pemetrexed 13Cisplatin 12Carboplatin 12Drug Therapy 10Gemcitabine 8Gefitinib 8Docetaxel 8camrelizumab 5apatinib 5Radiotherapy 5Paclitaxel 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Endostatins 5tislelizumab 4pembrolizumab 4endostar protein 4Simvastatin 4Bevacizumab 4anlotinib 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Etoposide 3toripalimab 2surufatinib 2olaparib 2durvalumab 2atezolizumab 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Sunitinib × Thoracic × Clear all
NCT00620347 2013-06-19

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

National Cancer Center, Korea

Phase 2 Completed
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡